Atara Biotherapeutics, Inc.

Ladies and gentlemen, thank you for standing by and welcome to the Atara Biotherapeutics Second Quarter 2020 Financial Results Conference Call. At this time, all participant lines are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 on your telephone. Please be advised that today's call is being recorded. I'd now like to hand the call over to Eric Heilengren, Vice President of Investor Relations and Finance at Atara Biotherapeutics. Thank you. Please go ahead, sir.

Thank you, operator. Good afternoon, everyone, and welcome to ATARA's second quarter 2020 conference call. On today's call, members from the ATARA executive team will provide an update on our financial results and operational progress and also review our upcoming key milestones and objectives for 2020. Earlier today, we issued a press release announcing our second quarter 2020 financial results and operational progress. This press release and an updated investor presentation are now available in the Investor and Media section at atarabio.com. Joining me on today's call are Dr. Pascal Tuchon, President and Chief Executive Officer, Dr. Jacob DuPont, Executive Vice President and Global Head of Research and Development, Upal Kopikar, Chief Financial Officer, Joe Newell, Chief Operations Officer, Dr. A.J. Joshi, Chief Medical Officer, and Kristen Urema, Chief Commercial Officer. We will begin with prepared comments from Pascal and Jacob, then open the call up for your questions. We would like to remind listeners that during the call, the company's management will be making forward-looking statements. Actual results could differ materially from those stated or implied by our forward-looking statements due to risks and uncertainties associated with the company's business. These forward-looking statements are qualified in their entirety by the cautionary statements contained in today's press release and the company's SEC filings. These statements are made as of today's date, and the company undertakes no obligation to update these statements. Now I'd like to turn the call over to Pascal. Pascal?

Thank you, Eric, and thank you all for joining us this afternoon.